Umbilical Cord vs Bone Marrow vs Fat-Derived Stem Cells

Three tissue sources supply almost all commercial stem cell treatment. Clinics tend to advocate strongly for whichever one they use. Here is the comparison without that thumb on the scale.

The comparison

	Bone marrow	Adipose (fat)	Umbilical cord
How obtained	Aspiration from pelvis, local anaesthetic	Mini-liposuction	Donated after healthy birth
Patient procedure	Yes — uncomfortable	Yes — minor surgical	None
MSC concentration	Low — a small fraction of the aspirate	Higher per volume	High
Cell quality	Declines with donor age and illness	Declines with age; better preserved than marrow	Young, consistent
Research history	Longest and best studied	Substantial	Growing
US regulatory status	Narrow exemption possible if minimally manipulated	SVF not lawfully marketable for these uses	Generally a biological drug; almost none licensed
Typical add-on cost	$5,000–$12,000 harvest	$5,000–$12,000 harvest	No harvest cost
Same-day	Usually	Usually	Yes

Bone marrow

The classic source and the one with the longest research record. Bone marrow aspirate concentrate (BMAC) is what most orthopaedic practices in the US use.

The honest limitation: MSCs make up a very small proportion of a marrow aspirate — often cited as roughly one in ten thousand to one in a hundred thousand nucleated cells. Concentrating it helps, but the final dose is modest, and it falls further with age.

The harvest is genuinely uncomfortable. Patients frequently describe a deep pressure sensation during aspiration.

Adipose tissue

Fat yields more mesenchymal cells per volume than marrow, and the harvest is a familiar minor surgical procedure.

The regulatory position in the US is the main constraint: processing fat to produce stromal vascular fraction is treated as more than minimal manipulation, and injecting it into a knee is not a homologous use. SVF is not lawfully marketable for these purposes, which is why much adipose-based treatment happens offshore.

Safety note: the most severe documented harm in this field — permanent blindness following injection into the eye — involved adipose-derived cells.

Umbilical cord tissue

Donated after healthy, screened births. No harvest procedure, young cells, consistent batches. On paper the most attractive option, and it is what most overseas clinics use.

Two real caveats.

First, regulatory: these are generally biological drugs in the US and require licensure that essentially none have obtained.

Second, quality control: because manufacturing is not FDA-supervised for unapproved products, what is in the vial depends entirely on the supplier. Independent testing of commercially sold cord products has repeatedly found far fewer living cells than advertised, and in some cases essentially none. There have also been serious bacterial infection outbreaks traced to contaminated cord preparations.

Does the source change the outcome?

There is no strong evidence that one source produces better clinical results than another for the conditions clinics treat. The knee osteoarthritis meta-analysis that found most benefit to be placebo-attributable pooled trials across sources.

Which means: choose based on harvest burden, cost, and how well the clinic can document what it is giving you — not on which source a clinic’s marketing calls superior.

Sources

1. US Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products; warning letters on SVF and cord products.
2. Centers for Disease Control and Prevention — investigations of infections associated with umbilical cord blood products.
3. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of RCTs. Frontiers in Medicine, 2025.

---